Miyazaki T, Nakajima W, Hatano M, Shibata Y, Kuroki Y, Arisawa T, et al. Visualization of AMPA receptors in living human brain with positron emission tomography. Nat Med 2020;26:281–8. https://doi.org/10.1038/s41591-019-0723-9.
Hatano M, Miyazaki T, Ishiwata Y, Nakajima W, Arisawa T, Kuroki Y, et al. Biodistribution and radiation dosimetry of the positron emission tomography probe for AMPA receptor, [11C]K-2, in healthy human subjects. Sci Rep 2021;11.
Arisawa T, Miyazaki T, Ota W, Sano A, Suyama K, Takada Y, et al. [11C]K-2 image with positron emission tomography represents cell surface AMPA receptors. Neurosci Res 2021;173:106–13. https://doi.org/10.1016/j.neures.2021.05.009.
Many clinical trials involving AMPA-PET have been performed, including physician-initiated clinical trials of automatic PET drug synthesizers. This is a list of tests that have been or are being conducted. The test details are linked to the test number (separate site).
|Study Title||Study No.||Subject||Number of cases||Period|
|Clinical trial to evaluate the efficacy and safety of [11C]K-2 in healthy volunteers||UMIN000020975||Healthy||8||2016/02/10 – end|
|The clinical trial to evaluate the efficacy of [11C]K-2 in refractory epilepsy patients undergoing anterior temporal lobectomy||UMIN000025090||Refractory epilepsy||8||2016/11/30 –|
|The clinical pilot study to examine the distribution of [11C]K-2 in depression, bipolar disease, schizophrenia, addiction,ASD,epilepsy and FTD patients in oreder to develope the novel diagnostic method in cross-sectional way toward these diseases||UMIN000025132||Mental ilness and healthy||110||2016/12/2 –|
|Clinical trial to examine the effective dose and the safety of [11C]K-2 synthesized by dedicated machine in healthy male volunteers||UMIN000026357||Healthy||12||2017/3/6 – end|
|The exploratory clinical trial to evaluate the efficacy of [11C]K-2 in stroke patients under rehabilitation.||UMIN000029952||Sequelae of cerebral infarction||20||2017/11/13 –|
|The clinical trial to examine the densities of AMPA receptors in epilepsy patients with [11C]K-2||UMIN000031624||Epilepsy||35||2018/4/1 –|
|Clinical trial to examine the effectiveness of AMPA-PET to identify epileptogenic focus in refractory epilepsy patients||JapicCTI-194576||Refractory epilepsy||40||2019/1/16 –|
|Investigator-initiated clinical trial to evaluate the efficacy of AMPA-PET in functional recovery process by rehabilitation for subjects registered in the clinical phase II trial of T-817MA (T817MAJP201R trial)||JapicCTI-194711||Stroke||10||2019/04/15 –|
|The relationship of AMPA receptor density with presence or absence of subsequent onset in high-risk cases of psychosis: A longitudinal PET study using [11C] K-2||jRCTs031190151||ARMS||30||2019/12/2 –|
|The relationship of AMPA receptor density in patients with autism spectrum disorder: A transversal PET study using [11C] K-2||jRCTs031190149||ASD||30||2019/12/2 –|
|The relationship of AMPA receptor density in patients with depression and bipolar disorder :a transversal PET study using [11C]K-2||jRCTs031190150||Depression, Bipolar disorder||60||2019/12/2 –|
|The relationship of AMPA receptor density in patients with schizophrenia: A transversal PET study using [11C] K-2||jRCTs031190197||Schizophrenia||30||2020/1/31 –|
|A pilot study to validate the estimate accuracy between standard uptake value ratio and non displaceable binding potential obtained from [11C]K-2 PET imaging in major cognitive disorders.||jRCTs031190262||Dementia||92||2020/4/2 –|
|A transversal PET study using [11C]K-2 to investigate age-and-sex-related changes AMPA receptor density in healthy volunteers.||jRCTs031200083||Healthy||100||2020/8/12 –|